RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hemagen Diagnostics Stock

Hemagen Diagnostics P/E 2024

Hemagen Diagnostics P/E

-0.51

Ticker

HMGN

ISIN

US4235011057

WKN

885724

As of Sep 21, 2024, Hemagen Diagnostics's P/E ratio was -0.51, a -27.14% change from the -0.7 P/E ratio recorded in the previous year.

The Hemagen Diagnostics P/E history

Hemagen Diagnostics Aktienanalyse

What does Hemagen Diagnostics do?

Hemagen Diagnostics Inc is a company that was founded in 1985. The company is based in Columbia, Maryland and is involved in medical diagnostics. Hemagen specializes in the development of diagnostic test kits that help doctors and laboratories identify and treat medical conditions and diseases. Hemagen Diagnostics offers a wide range of products in the field of diagnostics and medical research. Their offerings include diagnostic test kits for autoimmune diseases, infectious diseases, enzymes, proteins, and hormones. These test kits are used by medical professionals and laboratories worldwide. The business model of Hemagen Diagnostics is focused on providing its customers with the best diagnostic test kits on the market. The company has developed a wide range of products and services for a broad spectrum of medical conditions and diseases. Hemagen Diagnostics' core business is the production of test kits for laboratories and medical professionals. One of Hemagen Diagnostics' main areas of focus is disease diagnosis. The company has developed an extensive range of diagnostic test kits that facilitate the diagnosis of various diseases. This includes test kits for diseases such as HIV, hepatitis, and infectious diseases like chlamydia and gonorrhea. Hemagen also produces test kits for autoimmune diseases such as rheumatoid arthritis and lupus. Another focus of Hemagen Diagnostics is the development of test kits for medical research. The company has created a wide selection of test kits that can be used for research projects. This includes test kits for hormones, proteins, and enzymes. These test kits are suitable for a range of research applications such as biomarker identification and the study of metabolic processes. Over the years, Hemagen Diagnostics has expanded and improved its range of products and services. The company has continuously expanded and enhanced its division for the development of diagnostic test kits. It has also established a number of partnerships with other companies and institutes in the field of medical diagnostics. In conclusion, Hemagen Diagnostics Inc is a leading provider of diagnostic test kits for medical diagnostics and research. The company specializes in the development of state-of-the-art tests for disease diagnosis and the investigation of biomolecular processes. Hemagen Diagnostics has a strong reputation within the medical community and is continuously working on improving and expanding its product range. Hemagen Diagnostics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Hemagen Diagnostics's P/E Ratio

The Price to Earnings (P/E) Ratio of Hemagen Diagnostics is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Hemagen Diagnostics's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Hemagen Diagnostics is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Hemagen Diagnostics’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Hemagen Diagnostics stock

What is the price-to-earnings ratio of Hemagen Diagnostics?

The price-earnings ratio of Hemagen Diagnostics is currently -0.51.

How has the price-earnings ratio of Hemagen Diagnostics changed compared to last year?

The price-to-earnings ratio of Hemagen Diagnostics has increased by -27.14% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Hemagen Diagnostics high compared to other companies?

Yes, the price-to-earnings ratio of Hemagen Diagnostics is high compared to other companies.

How does an increase in the price-earnings ratio of Hemagen Diagnostics affect the company?

An increase in the price-earnings ratio of Hemagen Diagnostics would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Hemagen Diagnostics affect the company?

A decrease in the price-earnings ratio of Hemagen Diagnostics would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Hemagen Diagnostics?

Some factors that influence the price-earnings ratio of Hemagen Diagnostics are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Hemagen Diagnostics pay?

Over the past 12 months, Hemagen Diagnostics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hemagen Diagnostics is expected to pay a dividend of 0 USD.

What is the dividend yield of Hemagen Diagnostics?

The current dividend yield of Hemagen Diagnostics is .

When does Hemagen Diagnostics pay dividends?

Hemagen Diagnostics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hemagen Diagnostics?

Hemagen Diagnostics paid dividends every year for the past 0 years.

What is the dividend of Hemagen Diagnostics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hemagen Diagnostics located?

Hemagen Diagnostics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hemagen Diagnostics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hemagen Diagnostics from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Hemagen Diagnostics pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Hemagen Diagnostics in the year 2023?

In the year 2023, Hemagen Diagnostics distributed 0 USD as dividends.

In which currency does Hemagen Diagnostics pay out the dividend?

The dividends of Hemagen Diagnostics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hemagen Diagnostics

Our stock analysis for Hemagen Diagnostics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hemagen Diagnostics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.